See more : Parx Materials N.V. (PARPF) Income Statement Analysis – Financial Results
Complete financial analysis of SQZ Biotechnologies Company (SQZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SQZ Biotechnologies Company, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Genfit S.A. (GNFT.PA) Income Statement Analysis – Financial Results
- Madison Pacific Properties Inc. (MDPCF) Income Statement Analysis – Financial Results
- Emerson Electric Co. (0R33.L) Income Statement Analysis – Financial Results
- Eumundi Group Limited (EBG.AX) Income Statement Analysis – Financial Results
- Chularat Hospital Public Company Limited (CHG-R.BK) Income Statement Analysis – Financial Results
SQZ Biotechnologies Company (SQZ)
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 70.98M | 70.15M | 51.55M | 36.10M | 24.38M |
| General & Administrative | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Other Expenses | -449.00K | -8.00K | -13.00K | -791.00K | -1.13M |
| Operating Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 31.94M |
| Cost & Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 33.07M |
| Interest Income | 1.22M | 36.00K | 550.00K | 2.07M | 978.00K |
| Interest Expense | 9.72M | 0.00 | 0.00 | 0.00 | 59.00K |
| Depreciation & Amortization | 21.40M | 11.03M | 10.94M | 6.42M | 1.07M |
| EBITDA | -59.28M | -57.74M | -40.12M | -27.85M | -18.12M |
| EBITDA Ratio | -281.91% | -213.07% | -191.04% | -144.15% | -143.06% |
| Operating Income | -80.68M | -68.77M | -51.06M | -34.27M | -20.40M |
| Operating Income Ratio | -383.68% | -253.78% | -243.16% | -177.37% | -161.05% |
| Total Other Income/Expenses | 1.22M | 28.00K | 537.00K | 2.06M | 1.15M |
| Income Before Tax | -79.46M | -68.74M | -50.52M | -32.20M | -19.25M |
| Income Before Tax Ratio | -377.88% | -253.68% | -240.60% | -166.69% | -151.95% |
| Income Tax Expense | -1.22M | -36.00K | -550.00K | -7.00K | 1.21M |
| Net Income | -78.24M | -68.71M | -49.97M | -32.20M | -19.25M |
| Net Income Ratio | -372.08% | -253.54% | -237.98% | -166.66% | -151.95% |
| EPS | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| EPS Diluted | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| Weighted Avg Shares Out | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
| Weighted Avg Shares Out (Dil) | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial...
SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenerative medicine data showing that the company's Cell Squeeze® technology can be used to generate neurons from...
SQZ Biotechnologies' TAC Program Induces Multiple Mechanisms Of Antigen-Specific Tolerance, Animal Study Shows
SQZ Biotechnologies Company (NYSE: SQZ) has announced preclinical results from its Tolerizing Antigen Carrier (TAC) program, showing potential for application in various autoimmune diseases. Data will be presented at the 2021 Federation of Clinical Immunology Sciences annual meeting.
SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results from the company's Tolerizing Antigen Carrier (TAC) program demonstrating that its engineered TACs can drive antigen-specific...
SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV demonstrating that the investigational cell therapy is...
SQZ Biotech to Present at Jefferies Virtual Health Care Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. Armon Sharei, PhD, chief executive...
SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manufacturing, and antitumor activity data from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV-101 in patients with...
SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the period ended March 31, 2021 and reviewed recent business highlights. “We continue to execute across our...
SQZ Biotech to Present at BofA Securities 2021 Virtual Health Care Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the BofA (Bank of America) Securities 2021 Virtual Health Care Conference taking place May 11-13, 2021....
SQZ Biotech to Participate in April Investor Events
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in multiple investor conferences in April 2021. Armon Sharei, PhD, chief executive officer, will present a corporate...
Source: https://incomestatements.info
Category: Stock Reports